Pfizer partner BioNTech scores €100M debt financing to fund COVID-19 vaccine production in Europe

BioNTech's headquarters
BioNTech and partner Pfizer are in early human testing for their COVID-19 vaccine program. (BioNTech)

BioNTech and Pfizer are among the front-runners in the closely watched COVID-19 vaccine race, and as they simultaneously work through development and scale up manufacturing, BioNTech has scored a €100 million financing agreement to help fund production in Europe.

The European Investment Bank signed a debt financing deal with BioNTech—to be completed in two €50 million tranches—as the biotech advances its Pfizer-partnered COVID-19 vaccine program, BNT162. The partners entered human testing in Germany back in April, followed by a U.S. study that launched in early May. The funding will be contingent on the program reaching certain milestones.

The funds will help with ongoing development and with BioNTech's efforts to scale up for production in Europe. The biotech already operates three mRNA factories in Germany, and it has been working to add capacity for its COVID-19 vaccine program.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

The BNT162 program is testing four mRNA vaccines against COVID-19 so the partners can zero in on the most promising options. The companies inked their COVID-19 vaccine tie-up back in March.

RELATED: Pfizer, BioNTech gear up to produce 'millions' of COVID-19 vaccine doses by year-end

In April, the companies unveiled plans to produce “millions” of doses this year and potentially “hundreds of millions” in 2021. At the time, Cantor Fitzgerald analysts wrote that the team could begin producing doses “at risk” to be in a position to distribute as quickly as possible if and when they win approvals.

While Pfizer and BioNTech are in phase 1/2 testing, Moderna and AstraZeneca have moved to phase 2 and beyond. Meanwhile, U.S. authorities are planning phase 3 studies for Moderna, AstraZeneca and Johnson & Johnson later this year, The Wall Street Journal reported Wednesday. Pfizer could start a phase 3 trial as soon as July, a source told the newspaper.

RELATED: Pfizer tags 3 U.S. manufacturing sites for possible COVID-19 vaccine launch

BioNTech is focusing on production in Europe, and Pfizer has selected three U.S. sites—and one in Belgium—for its mRNA vaccine manufacturing. Those sites are in Michigan, Massachusetts and Missouri as well as Puurs, Belgium. Pfizer has said it plans to select other sites as well.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.